Journal article
Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii
Mei-Ling Han, Xiaofen Liu, Tony Velkov, Yu-Wei Lin, Yan Zhu, Darren J Creek, Christopher K Barlow, Heidi H Yu, Zhihui Zhou, Jing Zhang, Jian Li
FRONTIERS IN PHARMACOLOGY | FRONTIERS MEDIA SA | Published : 2019
Abstract
Background: Polymyxins are a last-line class of antibiotics against multidrug-resistant Acinetobacter baumannii. However, polymyxin resistance can emerge with monotherapy, highlighting the need for synergistic combination therapies. Polymyxins in combination with β-lactams have shown remarkable synergy against multidrug-resistant A. baumannii. Methods: Liquid chromatography-mass spectrometry-based metabolomics was conducted to investigate the metabolic perturbations in an A. baumannii clinical isolate, AB090342, in response to colistin (1 mg/L), sulbactam (128 mg/L), and their combination at 1, 4, and 24 h. Metabolomics data were analyzed using univariate and multivariate statistics, and met..
View full abstractGrants
Awarded by National Natural Science Foundation of China (NSFC)
Funding Acknowledgements
This research was supported by a research grant from the National Natural Science Foundation of China (NSFC 81628015). M-LH and Y-WL are recipients of the 2018 Faculty Bridging Fellowship, Monash University. JL is an Australian National Health and Medical Research Council Principal Research Fellow. TV and DC are Australian National Health and Medical Research Council Career Development Research Fellows.